Neuropathic Pain News and Research

RSS

Neuropathic pain is a type of pain that is caused by damage to the nervous system following an injury or illness and affects approximately 1% of the population.

International researchers discover genetic component of Idiopathic Generalized Epilepsy

An international team of researchers has discovered a significant genetic component of Idiopathic Generalized Epilepsy (IGE), the most common form of epilepsy.

17 Jun 2014

Discovery may lead to relief for victims of range of neurological disorders

University of Toronto biologists leading an investigation into the cells that regulate proper brain function, have identified and located the key players whose actions contribute to afflictions such as epilepsy and schizophrenia.

6 Jun 2014

Glenmark Pharmaceuticals opens new monoclonal antibody manufacturing facility in Switzerland

Glenmark Pharmaceuticals S.A (GPSA), a wholly-owned subsidiary of Glenmark Pharmaceuticals Limited, India (GPL), announced the opening of its new cGMP compliant monoclonal antibody manufacturing facility in La Chaux-de-Fonds, Switzerland. T

4 Jun 2014

$Nektar reports etirinotecan pegol Phase 2 study results in patients with Avastin-refractory high-grade glioma$

Nektar reports etirinotecan pegol Phase 2 study results in patients with Avastin-refractory high-grade glioma

Nektar Therapeutics announced today new data from an investigator-sponsored Phase 2 study of NKTR-102 (etirinotecan pegol) in patients with Avastin-refractory high-grade glioma conducted at Stanford Cancer Institute under the direction of Lawrence Recht, M.D., Professor of Neurology and Neurosurgery, with co-investigator Seema Nagpal, M.D., Clinical Assistant Professor of Neurology and Neurological Sciences, Stanford School of Medicine.

2 Jun 2014

New antibody appears to block sensations of pain, itching in mouse model

Duke University researchers have found an antibody that simultaneously blocks the sensations of pain and itching in studies with mice.

23 May 2014

NeuroMetrix announces marketing launch of NC-Stat DPNCheck in Japan

NeuroMetrix, Inc., an innovative health care company that develops wearable medical technology and point-of-care tests to help patients and physicians manage chronic pain, nerve diseases, and sleep disorders, today reported the marketing launch in Japan of NC-stat® DPNCheck®.

22 May 2014

UNC researchers find new enzyme target for treating chronic pain

Researchers at the UNC School of Medicine have found a new target for treating chronic pain: an enzyme called PIP5K1C.

22 May 2014

Researchers show how cone snails venom inhibits neuronal calcium channels to reduce neuropathic pain

The venom from marine cone snails, used to immobilize prey, contains numerous peptides called conotoxins, some of which can act as painkillers in mammals. A recent study in The Journal of General Physiology provides new insight into the mechanisms by which one conotoxin, Vc1.1, inhibits pain.

15 May 2014

Neuropathic pain features common in knee OA

Enough patients with knee osteoarthritis experience pain with neuropathic characteristics to warrant attempts to diagnose and classify these features, say researchers.

12 May 2014

Acorda gets FDA Complete Response Letter for PLUMIAZ Nasal Spray NDA

Acorda Therapeutics, Inc. today announced that the U.S. Food and Drug Administration has issued a Complete Response Letter (CRL) for the New Drug Application (NDA) for PLUMIAZ (diazepam) Nasal Spray for the treatment of people with epilepsy who experience cluster seizures.

2 May 2014

Neuropathic and psychogenic pain contribute to chronic musculoskeletal pain

A lack of appropriate treatment for neuropathic and psychogenic pain may cause patients with musculoskeletal pain to suffer a more chronic pain course, according to the latest results of an ongoing Japanese epidemiological study.

28 Apr 2014

Biologists identify how T-type channels change electrochemical signaling of heart and brain cells

Biologists have discovered how an outer shield over T-type channels change the electrochemical signaling of heart and brain cells. Understanding how these shields work will help researchers eventually develop a new class of drugs for treating epilepsy, cardiovascular disease and cancer.

26 Apr 2014

BDSI enrolls first patient in Clonidine Topical Gel Phase 3 trial for treatment of painful diabetic neuropathy

BioDelivery Sciences International, Inc. announced today the enrollment of the first patient in the RHAPSODY Study, a Phase 3 clinical trial of Clonidine Topical Gel for the treatment of painful diabetic neuropathy.

3 Apr 2014

Russian Ministry of Health approves Medivir's simeprevir for chronic hepatitis C genotype 1 infection

Medivir AB announced today that the Russian Ministry of Health has approved Sovriad (simeprevir) for the treatment of chronic hepatitis C genotype 1 infection, in combination with peginterferon alfa and ribavirin, in adults with compensated liver disease (including cirrhosis) who are treatment naïve or who have failed previous interferon therapy (pegylated or non-pegylated) with or without ribavirin. Russia will be the first country within EMEA to gain access to simeprevir, which represents a significant advance in hepatitis C treatment.

24 Mar 2014

Medivir announces phase III ATTAIN study of simeprevir inhibitor in treatment of adult patients with HCV

Medivir AB today announced that new phase III data for the once-daily protease inhibitor simeprevir have been presented at the Conference of the Asian Pacific Association for the Study of the Liver (APASL) in Brisbane, Australia.

19 Mar 2014

Knopp and NIAID collaborate to investigate eosinophil-lowering effects of dexpramipexole

Knopp Biosciences LLC today announced a second collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to investigate the eosinophil-lowering effects of the investigational drug dexpramipexole.

13 Mar 2014

Conditioned pain modulation decreases activity in human spinal cord, say researchers

Researchers have demonstrated that conditioned pain modulation (CPM), a measure of the brain's ability to regulate pain, decreases activity in the human spinal cord as visible via functional magnetic resonance imaging (fMRI).

10 Mar 2014

Novel scaffold protein regulates mu opioid receptor induced signaling activation

Researchers found initial confirmation that a novel scaffold protein previously unassociated with the mu opioid receptor (MOR) regulates MOR-induced signaling activation.

4 Mar 2014

New article explores risks associated with using herbal cannabis for rheumatic conditions

Patients with rheumatic conditions are in need of symptom relief and some are turning to herbal cannabis as a treatment option. However, the effectiveness and safety of medical marijuana to treat symptoms of rheumatic conditions such as rheumatoid arthritis, lupus, or fibromyalgia is not supported by medical evidence. A new article published in Arthritis Care & Research, a journal of the American College of Rheumatology, explores the risks associated with using herbal cannabis for medicinal purposes and advises healthcare providers to discourage rheumatology patients from using this drug as therapy.

3 Mar 2014

Study explores risks associated with using herbal cannabis for treatment of rheumatic conditions